CN112794902B - AP-2alpha antibody and application thereof in preparation of cervical cancer drugs - Google Patents

AP-2alpha antibody and application thereof in preparation of cervical cancer drugs Download PDF

Info

Publication number
CN112794902B
CN112794902B CN202110149762.8A CN202110149762A CN112794902B CN 112794902 B CN112794902 B CN 112794902B CN 202110149762 A CN202110149762 A CN 202110149762A CN 112794902 B CN112794902 B CN 112794902B
Authority
CN
China
Prior art keywords
monoclonal antibody
2alpha
leu
pro
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110149762.8A
Other languages
Chinese (zh)
Other versions
CN112794902A (en
Inventor
王泰华
陈卫国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wang Taihua
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110149762.8A priority Critical patent/CN112794902B/en
Publication of CN112794902A publication Critical patent/CN112794902A/en
Application granted granted Critical
Publication of CN112794902B publication Critical patent/CN112794902B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention discloses an AP-2alpha monoclonal antibody and application of a drug combination of the monoclonal antibody and bleomycin in preparing a drug for treating cervical cancer. The invention prepares AP-2alpha holoprotein by preparing a eukaryotic expression system, and obtains a monoclonal antibody with high affinity specifically aiming at the AP-2alpha protein by a hybridoma cell on the basis of the protein, and the monoclonal antibody has better effect of inhibiting the proliferation of cervical cancer cells. In addition, the monoclonal antibody and the bleomycin are coupled, so that the effect of inhibiting cancer cell proliferation is better than that of sorafenib when the monoclonal antibody or the bleomycin is used alone or the monoclonal antibody and the bleomycin are used in a coupling mode without coupling.

Description

AP-2alpha antibody and application thereof in preparation of cervical cancer drugs
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to an AP-2alpha monoclonal antibody and application of a drug combination thereof in preparation of a drug for treating cervical cancer.
Background
Cervical cancer is the most common gynecological malignancy. The age of the primary cancer is 30-35 years old, the invasive cancer is 45-55 years old, and the incidence of the primary cancer tends to be younger in recent years. The widespread application of cervical cytology screening in recent decades has made cervical cancer and precancerous diseases discovered and treated in early stages, and the incidence and mortality of cervical cancer have been significantly reduced.
Cervical cancer is a disease that is regulated by a multigene network. AP-2 is an important transcription factor family, and research shows that AP-2 plays an important regulation role in cervical cancer. Wherein the AP-2alpha plays an important role in cell growth and tumorigenesis in part by combining with the promoter region of the gene downstream of the AP-2alpha to promote the expression thereof. The oncogene ErbB2, which is widely overexpressed in cervical cancer, has been a target for therapeutic studies. Loss of function of ErbB2 in tumor cells will result in inhibition of cell growth and cause apoptosis. The recent research reports that the expression of the ErbB2 gene is down-regulated to promote the apoptosis of cervical cancer cells, thereby achieving the aim of treating the cervical cancer. Research shows that AP-2alpha is combined with the promoter of the oncogene ErbB2 gene to promote the transcription and protein expression of the ErbB2 gene, thereby showing the regulation and control function of AP-2alpha in the generation and development of cervical cancer.
CN 111647067A discloses an application of a monoclonal antibody of AP-2alpha and sorafenib combined drug in treating cervical cancer. However, the invention only simply mixes the monoclonal antibody and sorafenib to be used for treatment, but the technical personnel in the field know that sorafenib is a chemical drug, has poor targeting property, and is mainly used for clinically treating patients with advanced liver cancer which can not be operated, so that the sorafenib can cause damage or drug resistance to other organs or tissues regardless of being used alone or simply mixed with the monoclonal antibody, and has limited treatment effect on cervical cancer. In addition, the antigen used for screening the monoclonal antibody in the invention is only a part of AP-2alpha, and the spatial structure of the antigen is possibly different from that of the target protein, so that the screened monoclonal antibody is possibly defective in specificity and sensitivity.
Disclosure of Invention
The invention aims to solve the problems in the prior art and provides an AP-2alpha monoclonal antibody and application of a drug combination thereof in preparing a drug for treating cervical cancer.
Therefore, the invention provides an AP-2alpha monoclonal antibody, and the epitope bound by the monoclonal antibody is positioned at aa55-aa68 of the AP-2alpha protein; the amino acid sequence of aa55-aa68 is LSHTPNADFQPPYF.
Preferably, the monoclonal antibody of the invention is of the IgG1 subtype.
Preferably, the amino acid sequence of the antigen for monoclonal antibody preparation according to the present invention is shown in SEQ ID NO 2.
Preferably, the nucleotide sequence of the antigen for monoclonal antibody preparation of the present invention is shown in SEQ ID NO. 1.
In yet another aspect, the present invention also provides a pharmaceutical composition comprising the AP-2alpha monoclonal antibody of claim 1 and bleomycin.
Preferably, the AP-2alpha monoclonal antibody and bleomycin in the pharmaceutical composition of the invention are coupled together by SPDP.
Preferably, the molar ratio of the AP-2alpha monoclonal antibody to the bleomycin in the pharmaceutical composition is 1: 3-6.
Preferably, the dosage of the pharmaceutical composition of the invention is 5 mg/kg. Preferably, the invention is as described.
The invention prepares AP-2alpha holoprotein by preparing a eukaryotic expression system, and obtains a monoclonal antibody with high affinity specifically aiming at the AP-2alpha protein by a hybridoma cell on the basis of the protein, and the monoclonal antibody has better effect of inhibiting the proliferation of cervical cancer cells. In addition, the monoclonal antibody and the bleomycin are coupled, so that the effect of inhibiting cancer cell proliferation is better than that of sorafenib when the monoclonal antibody or the bleomycin is used alone or the monoclonal antibody and the bleomycin are used in a coupling mode without coupling.
Drawings
FIG. 1 is an SDS-PAGE pattern of AP-2alpha protein.
Detailed Description
The technical solution in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. It is to be understood that the embodiments described are only some of the embodiments of the invention, and not all of them.
The chemical reagents related to the invention are all made in China.
EXAMPLE 1 preparation of AP-2alpha protein
Cloning the nucleotide sequence (the specific sequence is shown as SEQ ID NO. 1) of the AP-2alpha protein after codon optimization into a eukaryotic expression vector (such as a plasmid),
the nucleotide sequence (the specific sequence is shown as SEQ ID NO. 1) of the codon-optimized AP-2alpha protein is taken as a template, and EcoRI and XhoI double enzyme cutting sites are respectively used for connection to construct pFase-AP-2 alpha-6His expression plasmid. The identified positive recombinant plasmid is sent to Huada biology company for sequence determination, the determined nucleotide sequence and the coded amino acid sequence are analyzed and compared by software, and the correctness of the reading frame is checked.
Transiently transfecting 293T cells with the identified correct pFase-AP-2 alpha-6His expression plasmid, harvesting cell culture supernatant after 72 hours, and carrying out affinity purification and secretion on the expressed AP-2alpha-6His protein by using a nickel column (GE medical treatment); the BCA kit (Biyun day) was used to determine concentration and purity by SDS-PAGE. The expression yield can reach 200mg/L by determination, and the purity of SDS-PAGE (shown in figure 1) is more than 95%. The protein after determination is frozen and stored at-80 ℃ for standby. Wherein the amino acid sequence of the expressed AP-2alpha protein is shown as SEQ ID NO. 2.
EXAMPLE 2 preparation of anti-AP-2 alpha monoclonal antibody
Immunizing BALB/c mice of 8 weeks with AP-2alpha protein, emulsifying the AP-2alpha protein and Freund's complete adjuvant in equal volume during first immunization, and inoculating the mice with abdominal cavity, wherein each mouse contains 50 μ g of protein; after 7 days, the AP-2alpha protein and Freund's incomplete adjuvant are emulsified in equal volume, and the mice are immunized by the second abdominal cavity inoculation way, wherein each mouse contains 50 mu g of protein; directly immunizing AP-2alpha protein by the abdominal cavity of the mice for the third time after 7 days, wherein each mouse is immunized by 50 microgrammes; on the 3 rd day after immunization, fusion of mouse spleen cells and mouse myeloma cells SP2/0 is carried out, and HAT selective culture medium is cultured; after 10 days, AP-2alpha protein is used as a coating antigen, cell supernatant is detected by indirect ELISA, positive hybridoma cells are screened, and a 4D7 strain cell strain is screened from the positive hybridoma cells.
Injecting 0.5mL of pristane into the abdominal cavity of 8-10-week-old Balb/c mice, and injecting 1 × 10 hybridoma cells (4D7 strain) into each mouse 7-10 days later6～2×106And 7-10 days later, extracting ascites of the mice, centrifuging at 1200r/min for 10 minutes at 2-8 ℃, and collecting supernatant. The monoclonal antibodies were purified using a ProteinG affinity column and the antibodies were split into 0.5 mL/tube and stored at-20 ℃ until needed.
Next, we entrusted Nanjing Kinshire to perform typing detection on the monoclonal antibody and to detect the identified epitope, and the results showed that the epitope bound by the IgG1 subtype of the monoclonal antibody against AP-2alpha protein of the present invention is located at aa55-aa68 (specifically, LSHTPNADFQPPYF in amino acid sequence) of AP-2alpha protein.
Example 3 conjugation of anti-AP-2 alpha monoclonal antibodies to bleomycin
SPDP (3- (2-pyridinedimercapto) propionic acid N-hydroxysuccinimide ester) is used as a connecting agent, the gram molecule ratio of an anti-AP-2 alpha monoclonal antibody to the SPDP is 1:12, the gram molecule ratio of bleomycin to the SPDP is 1:1, the thiolated antibody and the thiolated bleomycin are mixed and then added with DTT (dithiothreitol), a conjugate part is collected by SephadexG 25 column chromatography, the protein content is detected by a BCA method, and the conjugate is stored at-80 ℃ for later use. Detecting the conjugate by using an ultraviolet-visible spectrophotometry method and a mass spectrometry method, wherein the molar ratio of the antibody to the bleomycin in the conjugate is 1: 3-6 through determination.
Example 4 application of combination of anti-AP-2 alpha monoclonal antibody and bleomycin to cervical cancer
See patent CN 111647067 a for a detailed method, which is as follows:
taking out SiHa cells of human cervical cancer from a liquid nitrogen tank, rapidly passing through a water bath at 37 ℃, adding RPMI-1640 culture solution, blowing, beating and uniformly mixing, centrifuging at 1000r/min for 5min, removing supernatant, adding a proper amount of RPMI-1640 culture solution containing 10% bovine serum, blowing, beating into cell suspension, placing at 37 ℃ and 5% CO2Culturing in an incubator. Observing the growth condition of the cells, and when the cells grow to 80%, carrying out digestion by pancreatin for passage or standby.
After BALB/c nude mice grow adaptively for 1 week, SiHa cells in logarithmic growth phase are taken, trypsinized and prepared into 1 × 10 cells by PBS respectively7Single cell suspensions at/mL concentration were inoculated subcutaneously under sterile conditions in nude mice dorsal near right axilla, 0.2mL each. On the 6 th day after subcutaneous SiHa inoculation, 48 mice with tumor diameter of 5mm or more were selected, and the mice were divided into 6 groups according to the complete randomization grouping method, namely blank control group (group A), AP-2alpha monoclonal antibody group (group B), AP-2alpha monoclonal antibody + sorafenib (group C), AP-2alpha monoclonal antibody + bleomycin coupling group (group D)The group of the mycin (group E) and the group of the bleomycin (group F) were administered by intraperitoneal injection, and after administration for 24 days, the mice were sacrificed to calculate the tumor inhibition rate, and the specific dosages and results are shown in the following table.
Figure BDA0002931752560000041
Figure BDA0002931752560000051
Compared with the blank control group, the composition of the composition,*P＜0.05；**p is less than 0.01; in comparison with the group B,#P＜0.05。
the results show that the body weight of the mice begins to slowly and continuously increase from the beginning to the end of the intraperitoneal injection of the medicine, and the trend of the mice in each group is basically consistent. The tumor inhibition rate of the D group mice is 93.63 percent, the tumor inhibition rate is the highest, and the effect is better than that of the non-coupling (E group). The monoclonal antibody can be used together with the chemical bleomycin, has a good inhibition effect, has an effect of effectively promoting tumor cell apoptosis, has a better use effect after coupling, and provides a basis for clinical treatment.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Sequence listing
<110> Chen Wei nation
<120> AP-2alpha antibody and application thereof in preparation of cervical cancer drugs
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1317
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
atgaagatgt tgtggaaact gacagacaac ataaagtacg aggattgtga ggaccgacac 60
gatggcacca gtaatggcac tgcgcgcctg ccccagctgg ggacagtggg ccagagtccg 120
tacacaagcg ccccaccgct cagccatacc ccaaacgcag acttccaacc accctacttc 180
ccaccccctt atcagcctat ttacccccag agccaggatc cctacagtca cgtgaatgat 240
ccctactctc tgaacccact gcatgcccaa cctcaacccc agcacccagg gtggcctggc 300
cagcggcaga gccaggaatc aggactgctt catacccacc gagggttgcc ccatcaactg 360
tcaggccttg acccacgacg cgactacaga agacatgagg acctgctgca tggtccccac 420
gccctcagct ccggcctggg ggacctgtcc atccatagtt tgccgcacgc gattgaggaa 480
gttccccatg tcgaggatcc cggtatcaac attcctgacc agactgtgat aaagaaaggt 540
ccagtgtccc tcagtaagtc caattccaat gcggtttctg ccattccaat taataaggac 600
aacttgttcg ggggggtggt gaatccaaat gaggtctttt gttccgtgcc agggagactg 660
tcccttttgt cctcaaccag caaatacaag gtgaccgtgg ccgaagtgca gcggcggctc 720
tctccacccg aatgcttgaa cgcctcattg ctggggggag tcctgaggag ggccaagtcc 780
aaaaacgggg ggagaagcct gagggagaaa cttgacaaaa ttggtctgaa cctccccgct 840
ggacggagga aagcggctaa tgtgactctg ctgaccagcc tggtggaagg cgaagcggtg 900
cacctggcca gggattttgg ttacgtttgt gaaactgaat tccccgccaa ggccgtggcc 960
gagtttctga accgccagca ctctgatcca aatgagcaag tgactcgaaa aaacatgttg 1020
ttggccacca agcagatctg caaagaattt accgatctcc tggctcagga tcggtctccc 1080
ctgggcaatt caagaccaaa tccaatcctc gagcctggga tccagtcctg cctgacacac 1140
tttaatctga taagtcacgg ctttggctca cctgcagttt gcgctgccgt tacagctctg 1200
cagaattatt tgaccgaagc ccttaaagca atggataaga tgtacctgtc taataacccc 1260
aacagccata ctgacaataa cgccaagagc tcagacaagg aagaaaaaca cagaaaa 1317
<210> 2
<211> 439
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Lys Met Leu Trp Lys Leu Thr Asp Asn Ile Lys Tyr Glu Asp Cys
1 5 10 15
Glu Asp Arg His Asp Gly Thr Ser Asn Gly Thr Ala Arg Leu Pro Gln
20 25 30
Leu Gly Thr Val Gly Gln Ser Pro Tyr Thr Ser Ala Pro Pro Leu Ser
35 40 45
His Thr Pro Asn Ala Asp Phe Gln Pro Pro Tyr Phe Pro Pro Pro Tyr
50 55 60
Gln Pro Ile Tyr Pro Gln Ser Gln Asp Pro Tyr Ser His Val Asn Asp
65 70 75 80
Pro Tyr Ser Leu Asn Pro Leu His Ala Gln Pro Gln Pro Gln His Pro
85 90 95
Gly Trp Pro Gly Gln Arg Gln Ser Gln Glu Ser Gly Leu Leu His Thr
100 105 110
His Arg Gly Leu Pro His Gln Leu Ser Gly Leu Asp Pro Arg Arg Asp
115 120 125
Tyr Arg Arg His Glu Asp Leu Leu His Gly Pro His Ala Leu Ser Ser
130 135 140
Gly Leu Gly Asp Leu Ser Ile His Ser Leu Pro His Ala Ile Glu Glu
145 150 155 160
Val Pro His Val Glu Asp Pro Gly Ile Asn Ile Pro Asp Gln Thr Val
165 170 175
Ile Lys Lys Gly Pro Val Ser Leu Ser Lys Ser Asn Ser Asn Ala Val
180 185 190
Ser Ala Ile Pro Ile Asn Lys Asp Asn Leu Phe Gly Gly Val Val Asn
195 200 205
Pro Asn Glu Val Phe Cys Ser Val Pro Gly Arg Leu Ser Leu Leu Ser
210 215 220
Ser Thr Ser Lys Tyr Lys Val Thr Val Ala Glu Val Gln Arg Arg Leu
225 230 235 240
Ser Pro Pro Glu Cys Leu Asn Ala Ser Leu Leu Gly Gly Val Leu Arg
245 250 255
Arg Ala Lys Ser Lys Asn Gly Gly Arg Ser Leu Arg Glu Lys Leu Asp
260 265 270
Lys Ile Gly Leu Asn Leu Pro Ala Gly Arg Arg Lys Ala Ala Asn Val
275 280 285
Thr Leu Leu Thr Ser Leu Val Glu Gly Glu Ala Val His Leu Ala Arg
290 295 300
Asp Phe Gly Tyr Val Cys Glu Thr Glu Phe Pro Ala Lys Ala Val Ala
305 310 315 320
Glu Phe Leu Asn Arg Gln His Ser Asp Pro Asn Glu Gln Val Thr Arg
325 330 335
Lys Asn Met Leu Leu Ala Thr Lys Gln Ile Cys Lys Glu Phe Thr Asp
340 345 350
Leu Leu Ala Gln Asp Arg Ser Pro Leu Gly Asn Ser Arg Pro Asn Pro
355 360 365
Ile Leu Glu Pro Gly Ile Gln Ser Cys Leu Thr His Phe Asn Leu Ile
370 375 380
Ser His Gly Phe Gly Ser Pro Ala Val Cys Ala Ala Val Thr Ala Leu
385 390 395 400
Gln Asn Tyr Leu Thr Glu Ala Leu Lys Ala Met Asp Lys Met Tyr Leu
405 410 415
Ser Asn Asn Pro Asn Ser His Thr Asp Asn Asn Ala Lys Ser Ser Asp
420 425 430
Lys Glu Glu Lys His Arg Lys
435

Claims (1)

1. An AP-2alpha epitope peptide is characterized in that the position of the epitope peptide in the amino acid sequence of the AP-2alpha protein is aa55-aa 68; the amino acid sequence of the epitope peptide is LSHTPNADFQPPYF.
CN202110149762.8A 2021-02-03 2021-02-03 AP-2alpha antibody and application thereof in preparation of cervical cancer drugs Active CN112794902B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110149762.8A CN112794902B (en) 2021-02-03 2021-02-03 AP-2alpha antibody and application thereof in preparation of cervical cancer drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110149762.8A CN112794902B (en) 2021-02-03 2021-02-03 AP-2alpha antibody and application thereof in preparation of cervical cancer drugs

Publications (2)

Publication Number Publication Date
CN112794902A CN112794902A (en) 2021-05-14
CN112794902B true CN112794902B (en) 2022-02-25

Family

ID=75813965

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110149762.8A Active CN112794902B (en) 2021-02-03 2021-02-03 AP-2alpha antibody and application thereof in preparation of cervical cancer drugs

Country Status (1)

Country Link
CN (1) CN112794902B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393525A (en) * 2020-06-08 2020-07-10 北京广未生物科技有限公司 Monoclonal antibody of AP-2alpha and application thereof in preparing medicine for treating cervical cancer
CN111647067A (en) * 2020-07-02 2020-09-11 北京广未生物科技有限公司 Application of AP-2alpha antibody combined medicine in preparation of medicine for treating cervical cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109848A1 (en) * 2002-12-09 2004-06-10 Isis Pharmaceuticals, Inc. Modulation of AP-2 alpha expression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111393525A (en) * 2020-06-08 2020-07-10 北京广未生物科技有限公司 Monoclonal antibody of AP-2alpha and application thereof in preparing medicine for treating cervical cancer
CN111647067A (en) * 2020-07-02 2020-09-11 北京广未生物科技有限公司 Application of AP-2alpha antibody combined medicine in preparation of medicine for treating cervical cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AP2α重组腺病毒质粒的构建及其在大鼠骨髓间充质干细胞中的表达;毕杨，等;《中国生物制品学杂志》;20120201;第25卷(第1期);全文 *
Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription;M Beger，等;《Journal of molecular medicine》;20010630;第79卷(第5-6期);全文 *

Also Published As

Publication number Publication date
CN112794902A (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US6224868B1 (en) Reagent and processes for targeting mutant epidermal growth factor receptors
JPH04501719A (en) polypeptide
CN113755495B (en) Use of gene editing technology in the treatment of cancer
US8703917B2 (en) Epidermal growth factor receptor variants and pharmaceutical compositions thereof
CN111393525B (en) Monoclonal antibody of AP-2alpha and application thereof in preparing medicine for treating cervical cancer
CN107236046B (en) Recombinant human endostatin fusion protein and preparation method and application thereof
CN101591388A (en) A kind of soluble TNF acceptor mutant
CN112794902B (en) AP-2alpha antibody and application thereof in preparation of cervical cancer drugs
CN101717775B (en) Single-chain antibody gene of anti-human death receptor 5
CN111647067B (en) Application of AP-2alpha antibody combined medicine in preparation of medicine for treating cervical cancer
WO2022174451A1 (en) Multi-domain fusion protein having anti-cancer activity
CN111333710B (en) C20orf24 protein deletion mutant and application thereof
CN101302256B (en) Novel recombinant fusion molecule and antineoplastic treatment function thereof
CN113980133A (en) Antibody and application thereof in anti-tumor
CN114685670A (en) CLDN18.2 antibodies and uses thereof
CN102153644B (en) Antigenic peptide for dimerization of epidermal growth factor receptor
CN113583095A (en) Antitumor polypeptide and application thereof
CN113896804B (en) Chimeric Antigen Receptor (CAR) and uses thereof
CN114369581B (en) Recombinant adenovirus with anti-tumor immunity function, preparation method and application
CN113956359B (en) Antibody and application thereof in anti-tumor
CN115806623B (en) Application of Cathepsin L inhibition composition in cell expansion
WO2012048667A1 (en) Epidermal growth factor receptor variant lacking exon
CN113321730B (en) CLDN18.2 antibodies and uses thereof
CN114149499B (en) Monoclonal antibodies against human EMC10 and their use in the treatment and/or prevention of obesity
CN109897109B (en) Monoclonal antibody of antitumor marker protein and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Wang Taihua

Inventor after: Chen Weiguo

Inventor before: Chen Weiguo

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220127

Address after: 250002 No. 602, unit 1, building 1, No. 7, Jida Road, Shizhong District, Jinan City, Shandong Province

Applicant after: Wang Taihua

Address before: No.30, lianpenggang village, Yagang, liuzu Town, Xinxing County, Yunfu City, Guangdong Province, 527431

Applicant before: Chen Weiguo

GR01 Patent grant
GR01 Patent grant